These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26603497)

  • 1. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
    Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS
    J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
    Sahin H; Harman M; Cinar C; Bozkaya H; Parildar M; Elmas N
    J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of Functional MR Predicts Early Response in Post-doxorubicin Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma.
    Ou HY; Cheng YF; Chuang YH; Hsu HW; Chen CL; Lazo MZ; Weng CC; Yu CY; Tsang LL; Huang TL; Tong YS
    Dig Dis Sci; 2020 Aug; 65(8):2433-2441. PubMed ID: 31732907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization.
    Dong S; Ye XD; Yuan Z; Xu LC; Xiao XS
    Eur J Radiol; 2012 Mar; 81(3):472-7. PubMed ID: 21296517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
    Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
    Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
    Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
    Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma.
    Yuan Z; Ye XD; Dong S; Xu LC; Xu XY; Liu SY; Xiao XS
    Eur J Radiol; 2010 Jul; 75(1):e9-14. PubMed ID: 19540083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.